Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.69 |
| ▸ | SFRP1 | Q8N474 | 4/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4618337 | 0.89 | SFRP1 (0.72) | L3MBTL3SFRP1KMT2APOLBALDH1A1 | |
| SCHEMBL4616943 | 0.85 | SFRP1 (0.65) | L3MBTL3SFRP1USP2 | |
| SCHEMBL4617084 | 0.85 | SFRP1 (0.81) | L3MBTL3SFRP1USP2ALDH1A1SMN1; SMN2 | |
| SCHEMBL4618289 | 0.84 | MAPK1 (0.65) | SFRP1USP2POLBALDH1A1SMN1; SMN2 | |
| SCHEMBL4616427 | 0.84 | SFRP1 (0.60) | L3MBTL3SFRP1USP2KMT2AALDH1A1 | |
| SCHEMBL4617608 | 0.82 | SMN1; SMN2 (0.63) | SFRP1USP2KMT2APOLBALDH1A1 | |
| SCHEMBL4617736 | 0.81 | ALDH1A1 (0.72) | SFRP1POLBALDH1A1SMN1; SMN2HTT | |
| SCHEMBL4616512 | 0.80 | SFRP1 (0.74) | SFRP1POLBL3MBTL1 | |
| SCHEMBL16359721 | 0.79 | USP2 (0.69) | USP2ALDH1A1SMN1; SMN2LMNAMAPK1 | |
| SCHEMBL4619413 | 0.79 | SFRP1 (0.66) | SFRP1KMT2AALDH1A1SMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | WYETH (US) | 2006-12-07 | — | — | US | claimed |
| EP-1879859-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | Wyeth a Corporation of the State of Delaware (US) | 2008-01-23 | — | — | EP | disclosed |
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
| WO-2006124875-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | WYETH (US) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | SFRP1, SOS1, FZD7 | L3MBTL3 4802/4885SFRP1 1/4885USP2 2796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.